{"entity":{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","aka":[],"tldr":"Developed the anti-GD2 antibodies 3F8 and naxitamab that treat relapsed neuroblastoma.","summary":"Nai-Kong Cheung developed the murine anti-GD2 antibody 3F8 in the 1980s and its humanised successor naxitamab, which won FDA approval in 2020 for relapsed or refractory high-risk neuroblastoma in bone or bone marrow, and has led decades of MSKCC trials of antibody-based immunotherapy in children. His laboratory engineers bispecific antibodies and CAR T cells against GD2 and other paediatric targets.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheung%20NK%5BAuthor%5D%20neuroblastoma%20GD2"}],"tags":["paediatric","neuroblastoma","immunotherapy"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["monoclonal-antibody","bispecific-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["naxitamab-201"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Enid A. Haupt Chair in Pediatric Oncology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Neuroblastoma","Anti-GD2 antibodies","Paediatric immunotherapy","Antibody engineering"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheung%20NK%5BAuthor%5D%20neuroblastoma%20GD2"}],"papers":[{"title":"Naxitamab for high-risk neuroblastoma: a phase II trial","journal":"JCO","year":2020},{"title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","journal":"JCO","year":2012,"doi":"10.1200/JCO.2011.41.3807"}]},"route":"/people/nai-kong-cheung/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"naxitamab-201","kind":"trial","name":"Naxitamab Study 201","route":"/trials/naxitamab-201/"}]}}